Deutsch English Français

Contact

EP2287192

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2287192

EP2287192 - Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis [Right-click to bookmark this link]
Status	Patent revoked Status updated on 30.11.2018 Database last updated on 02.11.2024
Former	The patent has been granted Status updated on 28.06.2018
Most recent event Tooltip	30.11.2018	Revocation of patent	published on 02.01.2019 [2019/01]
Applicant(s)	For all designated states Novartis Vaccines and Diagnostics, Inc. Intellectual Property R338 P.O. Box 8097 Emeryville CA 94662-8097 / US
	[2011/08]
Inventor(s)	01 / Zimmerman, Deborah Lee c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	02 / Harrowe, Gregory c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	03 / Liu, Cheng c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	04 / Koths, Kirston c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	05 / Kavanaugh, W. Michael c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	06 / Long, Li c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	[2015/35]
Former [2011/08]	01 / Zimmerman, Deborah Lee c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	02 / Harrowe, Gregory c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	03 / Liu, Cheng c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	04 / Koths, Kirston c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	05 / Kavanaugh, W. Michael c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	06 / Long, Li c/o Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
Representative(s)	Marshall, Cameron John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[2015/35]
Former [2011/08]	Marshall, Cameron John Carpmaels & Ransford One Southampton Row London WC1B 5HA / GB
Application number, filing date	10178225.8	17.11.2003
	[2011/08]
Priority number, date	US20020426781P	15.11.2002 Original published format: US 426781 P
	[2011/08]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP2287192
	Date:	23.02.2011
	Language:	EN
	[2011/08]
	Type:	B1 Patent specification
	No.:	EP2287192
	Date:	26.08.2015
	Language:	EN
	[2015/35]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	19.01.2011
Classification	IPC:	C07K16/24, C07K16/28, C12N5/12, A61K39/395, A61P35/04, A61K31/663, A61K38/17, A61K38/19, G01N33/50	[2011/08]
	CPC:	C07K16/243 (EP); A61K38/193 (EP); A61P19/08 (EP); A61P35/00 (EP); A61P35/04 (EP); A61P43/00 (EP); (+) A61K2039/505 (EP); A61K2039/507 (EP); C07K2317/73 (EP); C07K2317/76 (EP) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2015/35]
Former [2011/08]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
Title	German:	Verfahren zur Prävention und Behandlung von Krebsmetastasen und Knochenschwund, der mit Krebsmetastasen assoziiert ist	[2011/08]
	English:	Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis	[2011/08]
	French:	Procédés de prévention et de traitement des métastases de cancer et perte osseuse associée aux métastases de cancer	[2011/08]
Biological material	This application mentions deposited biological material, check the file for details
Examination procedure	19.08.2011	Examination requested [2011/39]
	09.12.2011	Amendment by applicant (claims and/or description)
	18.07.2013	Despatch of a communication from the examining division (Time limit: M06)
	28.01.2014	Reply to a communication from the examining division
	19.02.2014	Despatch of a communication from the examining division (Time limit: M06)
	30.09.2014	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	07.10.2014	Reply to a communication from the examining division
	06.02.2015	Communication of intention to grant the patent
	16.06.2015	Fee for grant paid
	16.06.2015	Fee for publishing/printing paid
	16.06.2015	Receipt of the translation of the claim(s)
Parent application(s) Tooltip	EP03783587.3 / EP1572106
	EP10004581.4 / EP2246363
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030783587) is 23.08.2007
Opposition(s)	Opponent(s)	01 25.05.2016 31.05.2016 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		02 25.05.2016 31.05.2016 ADMISSIBLE Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543-4000 / US Opponent's representative Reitstötter Kinzebach Patentanwälte Sternwartstraße 4 81679 München / DE
		03 25.05.2016 31.05.2016 ADMISSIBLE Five Prime Therapeutics, Inc. Two Corporate Drive South San Francisco CA 94080 / US Opponent's representative Denison, Christopher Marcus Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB
		[N/P]
	Former [2017/36]
	Opponent(s)	01 25.05.2016 31.05.2016 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		02 25.05.2016 31.05.2016 ADMISSIBLE Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543-4000 / US Opponent's representative Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
		03 25.05.2016 31.05.2016 ADMISSIBLE Five Prime Therapeutics, Inc. Two Corporate Drive South San Francisco CA 94080 / US Opponent's representative Denison, Christopher Marcus Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB
	Former [2016/26]
	Opponent(s)	01 25.05.2016 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		02 25.05.2016 ADMISSIBLE Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543-4000 / US Opponent's representative Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
		03 25.05.2016 Five Prime Therapeutics, Inc. Two Corporate Drive South San Francisco CA 94080 / US Opponent's representative Brasnett, Adrian Hugh Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB
	04.07.2016	Invitation to proprietor to file observations on the notice of opposition
	16.01.2017	Reply of patent proprietor to notice(s) of opposition
	17.04.2018	Date of oral proceedings
	29.06.2018	Despatch of minutes of oral proceedings
	29.06.2018	Despatch of communication that the patent will be revoked
	08.11.2018	Legal effect of revocation of patent [2019/01]
Appeal following opposition	05.09.2018	Appeal received No. T2284/18
	08.11.2018	Result of appeal procedure: appeal of the proprietor withdrawn
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	07.10.2014	Request for further processing filed
	07.10.2014	Full payment received (date of receipt of payment) Request granted
	21.10.2014	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
	09.12.2011	Request for further processing filed
	09.12.2011	Full payment received (date of receipt of payment) Request granted
	23.12.2011	Decision despatched
Fees paid	Renewal fee
	22.09.2010	Renewal fee patent year 03
	22.09.2010	Renewal fee patent year 04
	22.09.2010	Renewal fee patent year 05
	22.09.2010	Renewal fee patent year 06
	22.09.2010	Renewal fee patent year 07
	22.09.2010	Renewal fee patent year 08
	14.11.2011	Renewal fee patent year 09
	13.11.2012	Renewal fee patent year 10
	18.11.2013	Renewal fee patent year 11
	10.11.2014	Renewal fee patent year 12
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	17.11.2003
	AT	26.08.2015
	BE	26.08.2015
	BG	26.08.2015
	CY	26.08.2015
	CZ	26.08.2015
	DK	26.08.2015
	EE	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	MC	26.08.2015
	NL	26.08.2015
	RO	26.08.2015
	SE	26.08.2015
	SI	26.08.2015
	SK	26.08.2015
	TR	26.08.2015
	IE	17.11.2015
	LU	17.11.2015
	GR	27.11.2015
	CH	30.11.2015
	LI	30.11.2015
	PT	28.12.2015
	[2017/39]
Former [2017/03]	AT	26.08.2015
	BE	26.08.2015
	CZ	26.08.2015
	DK	26.08.2015
	EE	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	MC	26.08.2015
	NL	26.08.2015
	RO	26.08.2015
	SE	26.08.2015
	SI	26.08.2015
	SK	26.08.2015
	IE	17.11.2015
	LU	17.11.2015
	GR	27.11.2015
	CH	30.11.2015
	LI	30.11.2015
	PT	28.12.2015
Former [2016/45]	AT	26.08.2015
	CZ	26.08.2015
	DK	26.08.2015
	EE	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	MC	26.08.2015
	NL	26.08.2015
	RO	26.08.2015
	SE	26.08.2015
	SI	26.08.2015
	SK	26.08.2015
	IE	17.11.2015
	LU	17.11.2015
	GR	27.11.2015
	CH	30.11.2015
	LI	30.11.2015
	PT	28.12.2015
Former [2016/36]	AT	26.08.2015
	CZ	26.08.2015
	DK	26.08.2015
	EE	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	MC	26.08.2015
	NL	26.08.2015
	RO	26.08.2015
	SE	26.08.2015
	SI	26.08.2015
	SK	26.08.2015
	LU	17.11.2015
	GR	27.11.2015
	CH	30.11.2015
	LI	30.11.2015
	PT	28.12.2015
Former [2016/34]	AT	26.08.2015
	CZ	26.08.2015
	DK	26.08.2015
	EE	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	MC	26.08.2015
	NL	26.08.2015
	RO	26.08.2015
	SE	26.08.2015
	SK	26.08.2015
	LU	17.11.2015
	GR	27.11.2015
	CH	30.11.2015
	LI	30.11.2015
	PT	28.12.2015
Former [2016/31]	AT	26.08.2015
	CZ	26.08.2015
	DK	26.08.2015
	EE	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	MC	26.08.2015
	NL	26.08.2015
	RO	26.08.2015
	SE	26.08.2015
	SK	26.08.2015
	LU	17.11.2015
	GR	27.11.2015
	PT	28.12.2015
Former [2016/28]	AT	26.08.2015
	CZ	26.08.2015
	DK	26.08.2015
	EE	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	MC	26.08.2015
	NL	26.08.2015
	RO	26.08.2015
	SE	26.08.2015
	SK	26.08.2015
	GR	27.11.2015
	PT	28.12.2015
Former [2016/23]	AT	26.08.2015
	CZ	26.08.2015
	DK	26.08.2015
	EE	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	NL	26.08.2015
	RO	26.08.2015
	SE	26.08.2015
	SK	26.08.2015
	GR	27.11.2015
	PT	28.12.2015
Former [2016/22]	AT	26.08.2015
	CZ	26.08.2015
	DK	26.08.2015
	EE	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	NL	26.08.2015
	SE	26.08.2015
	GR	27.11.2015
	PT	28.12.2015
Former [2016/21]	AT	26.08.2015
	DK	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	IT	26.08.2015
	NL	26.08.2015
	SE	26.08.2015
	GR	27.11.2015
	PT	28.12.2015
Former [2016/20]	AT	26.08.2015
	DK	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	NL	26.08.2015
	SE	26.08.2015
	GR	27.11.2015
	PT	28.12.2015
Former [2016/14]	AT	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	NL	26.08.2015
	SE	26.08.2015
	GR	27.11.2015
	PT	28.12.2015
Former [2016/11]	AT	26.08.2015
	ES	26.08.2015
	FI	26.08.2015
	SE	26.08.2015
	GR	27.11.2015
	PT	28.12.2015
Former [2016/10]	ES	26.08.2015
	FI	26.08.2015
	SE	26.08.2015
	GR	27.11.2015
	PT	28.12.2015
Former [2016/09]	FI	26.08.2015
	GR	27.11.2015
Documents cited:	Search	[AD]US5491065 (HALENBECK ROBERT F [US], et al) [AD] 1-15 * examples I-IV * * column 4, lines 33-39 *;
		[A]WO9929345 (JOLLA INST FOR EX MEDICINE [US], et al) [A] 1-15 * figure 3; example 4 *;
		[AD]US6025146 (PANDIT JAYVARDHAN [US], et al) [AD] 1-15* example 11 *;
		[A]US6117422 (LADNER MARTHA B [US], et al) [A] 1-15 * columns 3, 35-41 *;
		[IDA] - YONEDA T ET AL, "INHIBITION OF OSTEOLYTIC BONE METASTASIS OF BREAST CANCER BY COMBINED TREATMENT WITH THE BIPHOSPHONATE IBANDRONATE AND TISSUE INHIBITOR OF THE MATRIX METALLOPROTEINASE-2", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, (19970515), vol. 99, no. 10, ISSN 0021-9738, pages 2509 - 2517, XP000946362 [ID] 1,4-6,9,14,15 * the whole document * [A] 2,3,7,8,10-13 DOI: http://dx.doi.org/10.1172/JCI119435
		[AD] - LOKESHWAR B L ET AL, "Development and characterization of monoclonal antibodies to murine macrophage colony-stimulating factor.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 JUL 1988, (19880715), vol. 141, no. 2, ISSN 0022-1767, pages 483 - 488, XP002430404 [AD] 1-15 * the whole document *
		[A] - SHIOI A ET AL, "ENRICHMENT OF GENERATED MURINE OSTEOCLASTS", CALCIFIED TISSUE INTERNATIONAL, NEW YORK, NY, US, (1994), vol. 55, no. 5, ISSN 0171-967X, pages 387 - 394, XP008075572 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1007/BF00299320
		[AD] - MANCINO A T ET AL, "Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.", THE JOURNAL OF SURGICAL RESEARCH SEP 2001, (200109), vol. 100, no. 1, ISSN 0022-4804, pages 18 - 24, XP002430405 [AD] 1-15 * the whole document * DOI: http://dx.doi.org/10.1006/jsre.2001.6204
		[A] - NEALE S D ET AL, "MACROPHAGE COLONY-STIMULATING FACTOR AND INTERLEUKIN-6 RELEASE BY PERIPROSTHETIC CELLS STIMULATES OSTEOCLAST FORMATION AND BONE RESORPTION", JOURNAL OF ORTHOPAEDIC RESEARCH, THE JOURNAL OF BONE AND JOINT SURGERY, INC.,, US, (199909), vol. 17, no. 5, ISSN 0736-0266, pages 686 - 694, XP001013119 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1002/jor.1100170510
		[A] - SHERR C J ET AL, "INHIBITION OF COLONY-STIMULATING FACTOR-1 ACTIVITY BY MONOCLONAL ANTIBODIES TO THE HUMAN CSF-1 RECEPTOR", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, (19890515), vol. 73, no. 7, ISSN 0006-4971, pages 1786 - 1793, XP000568719 [A] 1-15 * the whole document *
		[A] - TAKAHASHI M ET AL, "Amino-terminal region of human macrophage colony-stimulating factor (M-CSF) is sufficient for its in vitro biological activity: Molecular cloning and expression of carboxyl-terminal deletion mutants of human M-CSF", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US LNKD- DOI:10.1016/0006-291X(89)92683-1, vol. 161, no. 2, ISSN 0006-291X, (19890615), pages 892 - 901, (19890615), XP024837490 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/0006-291X(89)92683-1
	Examination	EP0457804
	by applicant	US4179337
		WO8804300
		WO8809810
		US4816567
		US4837028
		US4847201
		WO8910134
		US4892538
		US4929700
		WO9011364
		EP0404097
		WO9100741
		US5019369
		US5032676
		US5057313
		WO9201047
		US5093246
		WO9211018
		WO9311161
		US5223409
		US5229275
		WO9325673
		US5283187
		US5283173
		WO9402602
		US5338665
		US5432018
		WO9520652
		US5443953
		US5491065
		US5498530
		US5530101
		WO9621029
		US5545807
		WO9630498
		US5565332
		US5567610
		WO9633735
		WO9634096
		US5573905
		US5585089
		US5585277
		WO9640987
		US5589369
		US5591669
		WO9709433
		US5693762
		US5733731
		WO9815833
		WO9824893
		US5776886
		WO9837177
		US5877293
		US5922545
		US5939598
		US6025146
		US6054287
		US6306393
		US2002004215
		US2002091240
		US2002199213
		US2003031667
		US2003092125
		US2003139348
	US2003190317
	US2003194404
	US2003199531
	WO03088921
	- CHAMBERS, BONE AND MINERAL RESEARCH, (1989), vol. 6, pages 1 - 25
	- GOTHLING ET AL., CLIN ORTHOP RELAT R, (1976), vol. 120, pages 201 - 228
	- KAHN ET AL., NATURE, (1975), vol. 258, pages 325 - 327
	- SUDA ET AL., ENDOCR REV, (1992), vol. 13, pages 66 - 80
	- WALKER, SCIENCE, (1973), vol. 180, page 875
	- WALKER, SCIENCE, (1975), vol. 190, pages 785 - 787
	- WALKER, SCIENCE, (1975), vol. 190, pages 784 - 785
	- ASH ET AL., NATURE, (1980), vol. 283, pages 669 - 670
	- KERBY ET AL., J. BONE MINER RES, (1992), vol. 7, pages 353 - 62
	- ATHANASOU ET AL., BONE MINER, (1988), vol. 3, pages 317 - 333
	- FELDMAN ET AL., ENDOCRINOLOGY, (1980), vol. 107, pages 1137 - 1143
	- ZHENG ET AL., HISTOCHEM J, (1991), vol. 23, pages 180 - 188
	- HAGENAARS ET AL., BONE MINER, (1989), vol. 6, pages 179 - 189
	- WIKTOR-JEDRZEJCZAK ET AL., PROC NATL ACAD SCI USA, (1990), vol. 87, pages 4828 - 4832
	- YOSHIDA ET AL., NATURE, (1990), vol. 345, pages 442 - 444
	- LACEY ET AL., CELL, (1998), vol. 93, pages 165 - 176
	- TSUDA ET AL., BIOCHEM BIOPHYS RES CO, (1997), vol. 234, pages 137 - 142
	- WONG ET AL., J EXP MED, (1997), vol. 186, pages 2075 - 2080
	- WONG ET AL., J BIOL. CHEM, (1997), vol. 272, pages 25190 - 25194
	- YASUDA ET AL., ENDOCRINOLOGY, (1998), vol. 139, pages 1329 - 1337
	- YASUDA ET AL., PROC NATL ACAD SCI US, (1998), vol. 95, pages 3597 - 3602
	- BLAIR ET AL., J CELL BIOL, (1986), vol. 102, pages 1164 - 1172
	- VAANANEN ET AL., HISTOCHEMISTRY, (1983), vol. 78, pages 481 - 485
	- WARSHAFSKY ET AL., BONE, (1985), vol. 6, pages 179 - 185
	- DAVIES ET AL., J CELL BIOL, (1989), vol. 109, pages 1817 - 1826
	- G6THLING ET AL., CLIN ORTHOP RELAT R, (1976), vol. 120, pages 201 - 228
	- MUNDY, PRIMER ON THE METABOLIC BONE DISEASES AND DISORDERS OF MINERAL METABOLISM, (1990), pages 18 - 22
	- FIXE AND PRALORAN, CYTOKINE, (1998), vol. 10, pages 3 - 7
	- MARTIN ET AL., CRITICAL REV. IN EUKARYOTIC GENE EXPRESSION, (1998), vol. 8, pages 107 - 23
	- PANDIT ET AL., SCIENCE, (1992), vol. 258, pages 1358 - 62
	- HAMILTON J. A., J LEUKOC BIOL., (1997), vol. 62, no. 2, pages 145 - 55
	- HAMILTON J, A., IMMUNO TODAY., (1997), vol. 18, no. 7, pages 313 - 7
	- FIXE AND PRALORAN, CYTOKINE, (1998), vol. 10, pages 32 - 37
	- KACINSKI ANN. MED., (1995), vol. 27, pages 79 - 85
	- SMITH ET AL., CLIN. CANCER RES., (1995), vol. 1, pages 313 - 25
	- SCHOLL ET AL., J. NATL. CANCER INST, (1994), vol. 86, pages 120 - 6
	- LIN ET AL., J. EXP. MED., (2001), vol. 93, pages 727 - 39
	- KAWASAKI ET AL., SCIENCE, (1985), vol. 230, page 291
	- CERRETTI ET AL., MOLECULAR IMMUNOLOGY, (1988), vol. 25, page 761
	- LADNER ET AL., EMBO JOURNAL, (1987), vol. 6, page 2693
	- KOHLER ET AL., NATURE, (1975), vol. 256, page 495
	- CLACKSON ET AL., NATURE, (1991), vol. 352, page 624628
	- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
	- ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 1062
	- ROSENBURG AND MOORE, Pluckthun in The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
	- HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
	- CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
	- SCATCHARD ET AL., ANN N.Y. ACAD. SCI., (1949), vol. 51, page 660
	- GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103
	- BRODEUR ET AL., Monoclonal Antibody Production Techniques and Applications, MARCEL DEKKER, INC., (1987), pages 51 - 63
	- MUNSON ET AL., ANAL. BIOCHEM., (1980), vol. 107, page 220
	- MORRISON, S. L. ET AL., "Chimeric Human Antibody Molecules; Mouse Antigen Binding Domains with Human Constant Region Domains", PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6841 - 6855
	- BOULIANNE, G. L. ET AL., NATURE, (1984), vol. 312, pages 643 - 646
	- JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
	- MORRISON ET AL., PROC. NATL. ACAD. SCI., U.S.A., (1984), vol. 81, pages 6851 - 6855
	- MORRISON; OI, ADV. IMMUNOL., (1988), vol. 44, pages 65 - 92
	- VERHOEYER ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
	- PADLAN, MOLEC. IMMUN., (1991), vol. 28, pages 489 - 498
	- PADLAN, MOLEC. IMMUNOL., (1994), vol. 31, no. 3, pages 169 - 217
	- KETTLEBOROUGH, C.A. ET AL., PROTEIN ENG, (1991), vol. 4, no. 7, pages 773 - 83
	- RIECHMANN, L. ET AL., NATURE, (1988), vol. 3 32, page 323
	- CO, M. S. ET AL., J. IMMUNOL., (1994), vol. 152, pages 2968 - 2976
	- CUNNINGHAM; WELLS SCIENCE, ALANINE SCANNING MUTAGENESIS, (1989), vol. 244, pages 1081 - 1085
	- JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, page 2551
	- JAKOBOVITS ET AL., NATURE, (1993), vol. 362, pages 255 - 258
	- BRUGGERMANN ET AL., YEAR IN IMMUNO., (1993), vol. 7, page 33
	- JESPERS, L. S. ET AL., BIO/TECHNOLOGY, (1994), vol. 12, pages 899 - 903
	- HOOGENBOOM ET AL., J. MOL. BIOL., (1991), vol. 227, page 381
	- MARKS ET AL., J. MOL. BIOL, (1991), vol. 222, pages 581 - 597
	- CLACKSON, T.; WELLS, J. A., TIBTECH, (1994), vol. 12, pages 173 - 184
	- BURTON, D. R.; BARBAS III, C. F., ADV. IMMUNOL., (1994), vol. 57, pages 191 - 280
	- WINTER, G. ET AL., ANNU. REV. IMMUNOL., (1994), vol. 12, pages 433 - 455
	- WATKINS, "Screening of Phage-Expressed Antibody Libraries by Capture Lift", METHODS IN MOLECULAR BIOLOGY, ANTIBODY PHAGE DISPLAY: METHODS AND PROTOCOLS, vol. 178, pages 187 - 193
	- METH. MOL. BIOL., (1997), vol. 70, pages 173 - 187
	- PEARSON; LIPMAN, PNAS USA, (1988), vol. 85, pages 2444 - 2448
	- LIPMAN; PEARSON, SCIENCE, (1985), vol. 222, page 1435
	- DEVEREAUX ET AL., NUC. ACIDS RES., (1984), vol. 12, pages 387 - 395
	- ALTSCHUL ET AL., MOL. BIOL., (1990), vol. 215, pages 403 - 410
	- KOTHS, MOL. REPROD. DEV., (199701), vol. 46, no. 1, pages 31 - 38
	- KABSCH, W. ET AL., BIOPOLYMERS, (1983), vol. 22, page 2577
	- LEHNINGER, Biochemistry, Second Edition, WORTH PUBLISHERS, INC. NY, (1975), pages 71 - 77
	- GROSS AND MEIENHOFER, The Peptides: Analysis, Synthesis, Biology, ACADEMIC PRESS, (1979), vol. 1-4
	- MERRIFIELD ET AL., J. AM. CHEM. SOC., (1963), vol. 85, page 2149
	- GILLMAN; SMITH, GENE, (1979), vol. 8, pages 81 - 97
	- ROBERTS, S. ET AL., NATURE, (1987), vol. 328, pages 731 - 734
	- T. E. CREIGHTON, Proteins: Structure and Molecular Properties, W. H. FREEMAN & CO., (1983), pages 79 - 86
	- DAYHOFF, Atlas of Protein Sequence and Structure, NATIONAL BIOCHEMICAL RESEARCH FOUNDATION, (1972), vol. 5, page 124
	- HIGGINS ET AL., GENE, (1988), vol. 73, pages 237 - 244
	- HIGGINS ET AL., METH. ENZYMOL., (1996), vol. 266, pages 383 - 402
	- PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 2444 - 2448
	- DEVEREUX ET AL., NUCLEIC ACIDS RESEARCH, (1984), vol. 12, no. 1, page 387
	- ALTSCHUL ET AL., J. MOLEC. BIOL., (1990), vol. 215, pages 403 - 410
	- ALTSCHUL ET AL., BLAST Manual, NCB NLM NIH
	- ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
	- NEEDLEMAN ET AL., J. MOL BIOL., (1970), vol. 48, pages 443 - 453
	- AUSUBEL, ET AL:, Protocols in Molecular Biology, JOHN WILEY & SONS, (1994), pages 6.0.3 - 6.4.10
	- SAMBROOK ET AL., Molecular Cloning: A Laboratory Manual, COLD SPRING HARBOR LABORATORY PRESS, (1989), pages 9.47 - 9.51
	- COUSSENS, L ET AL., NATURE, (1986), vol. 320, page 277
	- FELGNER ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 84, pages 7413 - 7417
	- MALONE ET AL., PROC. NATL ACAD. SCI. USA, (1989), vol. 86, pages 6077 - 6081
	- ITO ET AL., BIOCHEM. BIOPHYS. ACTA, (1990), vol. 1023, pages 124 - 132
	- J. P. BEHR, TETRAHEDRON LETT., (1986), vol. 27, pages 5861 - 5864
	- J. P. BEHR ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 6982 - 6986
	- LEVENTIS ET AL., BIOCHIM. INTER., (1990), vol. 22, pages 235 - 241
	- GAO ET AL., BIOCHIM. BIOPHYS. ACTA, (1991), vol. 1065, pages 8 - 14
	- BEHR ET AL., BIOCONJUGATE CHEM, (1994), vol. 5, pages 3 82 - 3 89
	- ZHOU ET AL., BIOCHIM. BIOPHYS. ACTA, (1991), vol. 939, pages 8 - 18
	- BALLAS ET AL., BIOCHIM. BIOPHYS. ACTA, (1988), vol. 939, pages 8 - 18
	- PINNADUWAGE ET AL., BIOCHIM. BIOPHYS. ACTA, (1989), vol. 985, pages 33 - 37
	- ROSE ET AL., BIOTECHNIQUE, (1991), vol. 10, pages 520 - 525
	- OHMORI N I ET AL., BIOCHEM BIOPHYS RES COMMUN, (19970627), vol. 235, no. 3, pages 726 - 9
	- POLLARD H ET AL., J BIOL CHEM, (1998), vol. 273, no. 13, pages 7507 - 11
	- LETSINGER, R. L., PROC NATL ACAD SCI USA, (1989), vol. 86, no. 17, pages 6553 - 6
	- FRIEDMANN, SCIENCE, (1989), vol. 244, pages 1275 - 1281
	- ANDERSON, NATURE, (1998), vol. 392, no. 6679, pages 25 - 30
	- VERMA, SCIENTIFIC AMERICAN, (1990), pages 68 - 84
	- MILLER, NATURE, (1992), vol. 357, page 455460
	- DEAN, CURR OPIN BIOTECHNOL, (2001), vol. 12, no. 6, pages 622 - 5
	- GEARY ET AL., CURR OPIN INVESTIG DRUGS, (2001), vol. 2, no. 4, pages 562 - 573
	- LETSINGER ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1989), vol. 86, pages 6553 - 6556
	- LEMAITRE ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1987), vol. 84, pages 648 - 652
	- KROL ET AL., BIOTECHNIQUES, (1988), vol. 6, pages 958 - 976
	- ZON, PHARM. RES., (1988), vol. 5, pages 539 - 549
	- GAUTIER ET AL., NUCL. ACIDS RES., (1987), vol. 15, pages 6625 - 6641
	- INOUE ET AL., NUCL. ACIDS RES., (1987), vol. 15, pages 6131 - 6148
	- INOUE ET AL., FEBS LETT, (1987), vol. 215, pages 327 - 330
	- SARVER ET AL., SCIENCE, (1990), vol. 247, pages 1222 - 1225
	- ROSSI, CURRENT BIOLOGY, (1994), vol. 4, pages 469 - 471
	- HASELOFF; GERLACH, NATURE, (1988), vol. 334, pages 585 - 591
	- ZAUG ET AL., SCIENCE, (1984), vol. 224, pages 574 - 578
	- ZAUG; CECH, SCIENCE, (1986), vol. 231, pages 470 - 475
	- ZAUG ET AL., NATURE, (1986), vol. 324, pages 429 - 433
	- BEEN; CECH, CELL, (1986), vol. 47, pages 207 - 216
	- SMITHIES ET AL., NATURE, (1985), vol. 317, pages 230 - 234
	- THOMAS; CAPECCHI, CELL, (1987), vol. 51, pages 503 - 512
	- THOMPSON ET AL., CELL, (1989), vol. 5, pages 313 - 321
	- HELENE, ANTICANCER DRUG DES., (1991), vol. 6, no. 6, pages 569 - 584
	- HELENE ET AL., ANN. N.Y. ACAD. SCI., (1992), vol. 660, pages 27 - 36
	- MAHER, BIOASSAYS, (1992), vol. 14, no. 12, pages 807 - 815
	- STEIN ET AL., NUCL. ACIDS RES., (1988), vol. 16, page 3209
	- SARIN ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1988), vol. 85, pages 7448 - 7451
	- SCOTT ET AL., SCIENCE, (1990), vol. 249, page 386
	- DEVLIN ET AL., SCIENCE, (1990), vol. 249, page 404
	- ROBERTS; SZOSTAK, PROC NATL ACAD SCI USA, (1997), vol. 94, pages 12297 - 303
	- WELLS; LOWMAN, CURR OPIN BIOTECHNOL, (1992), vol. 3, pages 355 - 62
	- LOWMAN, ANN REV BIOPHYS BIOMOL STRUCT, (1997), vol. 26, pages 401 - 24
	- TAKASAKI ET AL., NATURE BIOTECH, (1997), vol. 15, pages 1266 - 70
	- SUDA ET AL., "Modulation of osteoclast differentiation", ENDOCR. REV., (1992), vol. 13, pages 66 - 80
	- MARTIN; UDAGAWA, TRENDS ENDOCRINOL. METAB., (1998), vol. 9, pages 6 - 12
	- UDAGAWA ET AL., ENDOCRINOLOGY, (1989), vol. 125, pages 1805 - 13
	- UDAGAWA ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 7260 - 4
	- SASAKI ET AL., CANCER RES., (1998), vol. 58, pages 462 - 7
	- MANCINO ET AL., J. SURG. RES., (2001), vol. 100, pages 18 - 24
	- MANCINO ET AL., J. SURG. RES., (2001), vol. 0, pages 18 - 24
	- INGALL, PROC. SOC. EXP. BIOL. MED., (1964), vol. 117, pages 819 - 22
	- FALASKO, CLIN. ORTHOP., (1982), vol. 169, pages 20 - 7
	- POWLES ET AL., BR. J. CANCER, (1973), vol. 28, pages 316 - 21
	- AUGUELLO ET AL., CANCER RES., (1988), vol. 48, pages 6876 - 81
	- SASAKI ET AL., CANCER RES., (1995), vol. 55, pages 3551 - 7
	- YONEDA ET AL., J. CLIN. INVEST., (1997), vol. 99, pages 2509 - 17
	- CLOHISY; RAMNARAINE, ORTHOP RES, (1998), vol. 16, pages 660 - 6
	- YIN ET AL., J. CLIN. INVEST., (1999), vol. 103, pages 197 - 206
	- FILDERMAN ET AL., CANCER RES, (1992), vol. 52, page 36616
	- WENGER ET AL., CLIN. EXP. METASTASIS, (2002), vol. 19, pages 169 - 73
	- YI ET AL., CANCER RES., (2002), vol. 62, pages 917 - 23
	- TSUTSUMI ET AL., CANCER LETT, (2001), vol. 169, pages 77 - 85
	- TSINGOTJIDOU ET AL., ANTICANCER RES, (2001), vol. 21, pages 971 - 8
	- WAKABAYASHI ET AL., ONCOLOGY, (2000), vol. 59, pages 75 - 80
	- CULP; KOGERMAN, FRONT BIOSCI., (1998), vol. 3, pages D672 - 83
	- RUNGE ET AL., INVEST RADIOL, vol. 32, pages 212 - 7
	- SHIODA ET AL., J. SURG. ONCOL., (1997), vol. 64, pages 122 - 6
	- MA ET AL., INVEST OPHTHALMOL VIS SCI, (1996), vol. 37, pages 2293 - 301
	- KURUPPU ET AL., J GASTROENTEROL HEPATOL, (1996), vol. 11, pages 26 - 32
	- WILLIAMS, MEDICINAL RESEARCH REVIEWS, (1991), vol. 11, pages 147 - 184
	- SWEETNAM ET AL., J. NATURAL PRODUCTS, (1993), vol. 56, pages 441 - 455
	- HODGSON, BIO/TECHNOLOGY, (1992), vol. 10, pages 973 - 980
	- STROSBERG ET AL., TRENDS IN PHARMACOLOGICAL SCIENCES, (1992), vol. 13, pages 95 - 98
	- PAUSCH, TRENDS IN BIOTECHNOLOGY, (1997), vol. 15, pages 487 - 494
	- VANDEN BROECK, INT. REV. CYTOLOGY, (1996), vol. 164, pages 189 - 268
	- JAYAWICKREME ET AL., CURRENT OPINION IN BIOTECHNOLOGY, (1997), vol. 8, pages 629 - 634
	- GERHARDT ET AL., EUR. J. PHARMACOLOGY, (1997), vol. 334, pages 1 - 23
	- BAINDUR ET AL., DRUG DEV. RES., (1994), vol. 33, pages 373 - 398
	- ROGERS, DRUG DISCOVERY TODAY, (1997), vol. 2, pages 156 - 160
	- WILLIAMS, MED. RES. REV., (1991), vol. 11, pages 147 - 184
	- NAKAYAMA, CUR. OPINION DRUG DISC. DEV., (1998), vol. 1, pages 85 - 91
	- BOSSé ET AL., J. BIOMOLECULAR SCREENING, (1998), vol. 3, pages 285 - 292
	- HILL, CUR. OPINION DRUG DISC. DEV., (1998), vol. 1, pages 92 - 97
	- SCIENCE, (1998), vol. 282, pages 63 - 68
	- MYERS, CURR. OPIN. BIOTECHNOL., (1997), vol. 8, pages 701 - 707
	- FIELDS ET AL., NATURE, (1989), vol. 340, pages 245 - 246
	- FIELDS ET AL., TRENDS IN GENETICS, (1994), vol. 10, pages 286 - 292
	- WIEBOLDT ET AL., ANAL. CHEM., (1997), vol. 69, pages 1683 - 1691
	- A.H. LIN ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (1997), vol. 41, no. 10, pages 2127 - 2131
	- CENCI ET AL., J CLIN. INVEST., (2000), vol. 1055, pages 1279 - 87
	- SHIH ET AL., INT. J. CANCER, (1988), vol. 41, pages 832 - 839
	- SHIH ET AL., INT. J. CANCER, (1990), vol. 46, pages 1101 - 1106
	- "Modification of Antibodies by Chemical Methods", UPESLACIS ET AL., Monoclonal Antibodies: Principles and Applications, WILEY-LISS, INC., (1995), pages 187 - 230
	- "Production and Characterization of Synthetic Peptide-Derived Antibodies", PRICE ET AL., Monoclonal Antibodies: Production, Enineering and Clinical Application, CAMBRIDGE UNIVERSITY PRESS, (1995), pages 60 - 84
	- LEUNG ET AL., J. IMMUNOL., (1995), vol. 154, page 5919
	- BOLETI ET AL., ANN. ONCOL., (1995), vol. 6, page 945
	- NICOLET ET AL., CANCER GENE THER, (1995), vol. 2, page 161
	- BECKER ET AL., PROC. NAT'L ACAD. SCI. USA, (1996), vol. 93, page 7826
	- HANK ET AL., CLIN. CANCER RES., (1996), vol. 2, page 1951
	- HU ET AL., CANCER RES., (1996), vol. 56, page 4998
	- YANG ET AL., HUM. ANTIBODIES HYBRIDOMAS, (1995), vol. 6, page 129
	- CHAUDHARY ET AL., NATURE, (1989), vol. 339, page 394
	- BRINKMANN ET AL., PROC. NAT'L ACAD. SCI. USA, (1991), vol. 88, page 8616
	- BATRA ET AL., PROC. NAT'L ACAD. SCI. USA, (1992), vol. 89, page 5867
	- FRIEDMAN ET AL., J. MUNUNOL., (1993), vol. 150, page 3054
	- WELS ET AL., INT. J. CAN., (1995), vol. 60, page 137
	- FOMINAYA ET AL., J. BIOL. CHEM., (1996), vol. 271, page 10560
	- KUAN ET AL., BIOCHEMISTRY, (1996), vol. 35, page 2872
	- SCHMIDT ET AL., INT. J. CAN., (1996), vol. 65, page 538
	- KREITMAN ET AL., LEUKEMIA, (1993), vol. 7, page 553
	- NICHOLLS ET AL., J. BIOL. CHEM., (1993), vol. 268, page 5302
	- THONIPSON ET AL., J. BIOL. CHEM., (1995), vol. 270, page 28037
	- VALLERA ET AL., BLOOD, (1996), vol. 88, page 2342
	- DEONARAIN ET AL., TUMOR TARGETING, (1995), vol. 1, page 177
	- LINARDOU ET AL., CELL BIOPHYS, (1994), vol. 24-25, page 243
	- DOHLSTEN ET AL., PROC. NAT'L ACAD. SCI. USA, (1994), vol. 91, page 8945
	- PASTAN ET AL., CELL, (1986), vol. 47, page 641
	- GOLDENBERG, CA, A CANCER JOURNAL FOR CLINICIANS, (1994), vol. 44, page 43
	- LOKESHWAR, B. L.; LIN, H. S., J IMMUNOL., (1988), vol. 141, no. 2, pages 483 - 8
	Opposition	US5491065
		WO9929345
		WO0130381
		WO9009400
		EP1572106
		- ABRAMS et al., "Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.", Molecular Cancer Therapeutics, (20030000), vol. 2, no. 10, pages 1011 - 2021, XP009070150
		- TANAKA et al., "Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors.", Journal of Clinical Investigation, (19930000), vol. 91, no. 1, pages 257 - 263, XP055291049 DOI: http://dx.doi.org/10.1172/JCI116179
		- LIN et al., "The macrophage growth factor CSF-1 in mammary gland development and tumor progression.", Journal of Mammary Gland Biology and Neoplasia, (20020000), vol. 7, no. 2, pages 147 - 162, XP055291051 DOI: http://dx.doi.org/10.1023/A:1020399802795
		- LIN et al., "Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.", Journal of Experimental Medicine, (20010000), vol. 193, no. 6, pages 727 - 739, XP055059258 DOI: http://dx.doi.org/10.1084/jem.193.6.727
		- CLOHISY et al., "Review of cellular mechanisms of tumor osteolysis.", Clinical Orthopaedics and Related Research, (20000000), vol. 373, pages 104 - 114, XP055291190 DOI: http://dx.doi.org/10.1097/00003086-200004000-00013
		- LEES et al., "Macrophage Colony Stimulating Factor Increases Bone Resorption in Dispersed Osteoclast Cultures by Increasing Osteoclast Size", Journal of bone and mineral research, (19990000), vol. 14, no. 6, pages 937 - 945, XP055291192 DOI: http://dx.doi.org/10.1359/jbmr.1999.14.6.937
		- MANCINO et al., "Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.", Journal of Surgical Research, (20010000), vol. 100, pages 18 - 24, XP055291193 DOI: http://dx.doi.org/10.1006/jsre.2001.6204
		- CENCI et al., "M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone loss", Journal of Clinical Investigation, (20000000), vol. 105, no. 9, pages 1279 - 1287, XP055291195 DOI: http://dx.doi.org/10.1172/JCI8672
		- YONEDA et al., "Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.", Cancer Supplement, (20000000), vol. 88, no. 12, pages 2979 - 2988, XP002323809 DOI: http://dx.doi.org/10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U
		- AHARINEJAD et al., "Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice.", Cancer Research, (20020000), vol. 62, no. 18, pages 5317 - 5324, XP002247522
		- MURRAY et al., "SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model", Clinical & Experimental Metastasis, (20030000), vol. 20, no. 8, pages 757 - 766, XP019235730 DOI: http://dx.doi.org/10.1023/B:CLIN.0000006873.65590.68
		- ROCERETO et al., "Phase II Study of Mifepristone (RU486) in Refractory Ovarian Cancer", Gynecologie Oncology, (20000000), vol. 77, no. 3, pages 429 - 432, XP002378774 DOI: http://dx.doi.org/10.1006/gyno.2000.5789
		- KACINSKI, "CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract.", Molecular Reproduction and Development, (19970000), vol. 46, no. 1, pages 71 - 74, XP055291210 DOI: http://dx.doi.org/10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6
		- KAWAMOTO et al., "CT of Epithelial Ovarian Tumors", RadioGraphics, (19990000), vol. 19, no. Suppl. 1., pages S85 - S102, XP055291218 DOI: http://dx.doi.org/10.1148/radiographics.19.suppl_1.g99oc10s85
		- SAPI et al., "Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids.", Oncogene, (19950000), vol. 10, no. 3, pages 529 - 542, XP055291224
		- KATHRYN B. HORWITZ, "B9 Antiprogestins and the Treatment of Breast Cancer", KATHRYN B. HORWITZ, Laneta Dorflinger, Sarah S. Brown, and Leslie Z. Benet, Molla S. Donaldson, Clinical Applications of Mifepristone (RU 486) and Other Antiprogestins, (19930000), pages 210 - 228, ISBN 0309049490, XP055291235
		- Zetter, B., "ANGIOGENESIS AND TUMOR METASTASIS", Annual Review of Medicine, (19980000), vol. 49, no. 1, pages 407 - 424, XP055291238 DOI: http://dx.doi.org/10.1146/annurev.med.49.1.407
		- SHERR et al., "Inhibition of Colony-Stimulating Factor-i Activity by Monoclonal Antibodies to the Human CSF-1 Receptor", Blood, (19890000), vol. 73, no. 7, pages 1786 - 1793, XP002570336
		- Yang T T; A; Sabokbar; Gibbons C L M H; Athanasou N A, "Human mesenchymal tumour-associated macrophages differentiate into osteoclastic bone-resorbing cells", THE JOURNAL OF BONE AND JOINT SURGERY,, (20020401), vol. 84-B, pages 452 - 456, XP055466410
		- ABRAMS et al., "Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with standard of care therapeutic agents for the treatment of breast cancer", Molecular Cancer Therapeutics, (20030000), vol. 2, no. 10, pages 1011 - 1021, XP009070150
		- LIN et al., "The Macrophage Growth Factor CSF-1 in Mammary Gland Development and Tumor Progression", Journal of Mammary Gland Biology and Neoplasia, (20020000), vol. 7, no. 2, pages 147 - 162, XP055291051 DOI: http://dx.doi.org/10.1023/A:1020399802795
		- LIN et al., "Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy", Journal of Experimental Medicine, (20010000), vol. 193, no. 6, pages 727 - 740, XP055059258 DOI: http://dx.doi.org/10.1084/jem.193.6.727
		- MANCINO et al., "Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells", Journal of Surgical Research, (20010000), vol. 100, no. 1, pages 18 - 24, XP003013598 DOI: http://dx.doi.org/10.1006/jsre.2001.6204
		- YONEDA et al., "Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma", Cancer Supplement, (20000000), vol. 88, no. 12, pages 2979 - 2988, XP002323809 DOI: http://dx.doi.org/10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U
		- AHARINEJAD et al., "Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice", Cancer Research, (20020000), vol. 62, pages 5317 - 24, XP002610330 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-04-0961
		- MURRAY et al., "SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model", Clinical & Experimental Metastasis, (20030000), vol. 20, pages 757 - 766, XP019235730 DOI: http://dx.doi.org/10.1023/B:CLIN.0000006873.65590.68
		- ROCERETO et al., "Phase II study of Mifepristone (RU486) in refractory ovarian cancer", Gynecologie Oncology, (20000000), vol. 77, no. 3, pages 429 - 432, XP002378774 DOI: http://dx.doi.org/10.1006/gyno.2000.5789
		- KACINSKI, "CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract", Molecular Reproduction and Development, (19970000), vol. 46, no. 1, pages 71 - 74, XP055291210 DOI: http://dx.doi.org/10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6
		- KAWAMOTO et al., "CT of Epithelial Ovarian Tumors", RadioGraphics, (19990000), vol. 19, pages S85 - S102, XP055291218 DOI: http://dx.doi.org/10.1148/radiographics.19.suppl_1.g99oc10s85
		- HORWITZ et al., "B9 Antiprogestins and the Treatment of Breast Cancer", HORWITZ et al., Molla S. Donaldson, Laneta Dorflinger, Sarah S. Brown, And Leslie Z. Benet,, Clinical Applications of Mifepristone ( RU 486) and Other Antiprogestins, Washington , D.C., (19930000), pages 210 - 228, ISBN 978-0-309-04949-8, XP055291235
		- ZETTER, "ANGIOGENESIS AND TUMOR METASTASIS", Annual Review of Medicine, (19980000), vol. 49, no. 1, pages 407 - 424, XP055291238 DOI: http://dx.doi.org/10.1146/annurev.med.49.1.407
		- SHERR et al., "Inhibition of colony-stimulating factor-1 activity by monoclonal antibodies to the human CSF-1 receptor", Blood, (19890000), vol. 73, no. 7, pages 1786 - 1793, XP002570336
		- LOKESHWAR B L; LIN HSIU-SAN, "Development and characterization of monoclonal antibodies to murine macrophage colony-stimulating factor", THE JOURNAL OF IMMUNOLOGY, vol. 141, no. 2, (19880715), pages 483 - 488, XP002430404
		- SHERR C J; ET AL, "Inhibition of colony-stimulating factor-1 activity by monoclonal antibodies to the human CSF-1 receptor", Blood, vol. 73, no. 7, (19890000), pages 1786 - 1796, XP002570336
		- FELIX et al., "MACROPHAGE COLONY STIMULATING FACTOR RESTORES IN VIVO BONE RESORPTION IN THE OP/OP OSTEOPETROTIC MOUSE", Endocrinology, (19900000), vol. 127, no. 5, pages 2592 - 2594, XP055291296
		- S Tanaka et al, "Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors.", JOURNAL OF CLINICAL INVESTIGATION, vol. 91, no. 1, (19930000), pages 257 - 263, XP055291049 DOI: http://dx.doi.org/10.1172/JCI116179
		- SHIOI et al., "Enrichment of Generated Murine Osteoclasts", Calcif. Tissue Int., (19941100), vol. 55, no. 5, pages 387 - 394, XP008075572 DOI: http://dx.doi.org/10.1007/BF00299320
		- YONEDA et al., "Osteolytic Bone Metastasis in Breast Cancer", Breast Cancer Research and Treatment, (19940000), vol. 32, no. 1, pages 73 - 84, XP055291302 DOI: http://dx.doi.org/10.1007/BF00666208
		- CLOHISY et al., "Tumor osteolysis in osteopetrotic mice.", J Orthop. Res., (19950000), vol. 13, no. 6, pages 892 - 897, XP055291305 DOI: http://dx.doi.org/10.1002/jor.1100130613
		- Cecchini MG. et al, "Role of CSF-1 in bone and bone marrow development.", Mol Reprod Dev., vol. 46, no. 1, (19970100), pages 83 - 84, XP055291308 DOI: http://dx.doi.org/10.1002/(SICI)1098-2795(199701)46:1<75::AID-MRD12>3.0.CO;2-2
		- Clohisy DR et al, "Osteoclasts are required for bone tumors to grow and destroy bone.", J. Orthopaedic Research, (19981100), vol. 16, no. 6, pages 660 - 666, XP055291310 DOI: http://dx.doi.org/10.1002/jor.1100160606
		- NEALE et al., "Macrophage colony-stimulating factor and interleukin-6 release by periprosthetic cells stimulates osteoclast formation and bone resorption", Journal of Orthopaedic Research, (19990000), vol. 17, no. 5, pages 686 - 694, XP001013119 DOI: http://dx.doi.org/10.1002/jor.1100170510
		- SUDA et al., "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.", Endocr Rev., (19990000), vol. 20, no. 3, pages 345 - 357, XP055291315 DOI: http://dx.doi.org/10.1210/edrv.20.3.0367
		- JIMI et al., "Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.", J Immunol., (19990000), vol. 163, no. 1, pages 434 - 442, XP055291321
		- SAPI et al., "The Role of CSF-1 in Normal and Neoplastic Breast Physiology", Proc Soc Exp Biol Med., (20000000), vol. 220, no. 1, pages 1 - 8, XP055291323
		- Clohisy, Denis R. et al, "Review of Cellular Mechanisms of Tumor Osteolysis.", Clinical Orthopaedics & Related Research, vol. 373, (20000401), pages 104 - 114, XP055291190 DOI: http://dx.doi.org/10.1097/00003086-200004000-00013
		- LIN et al., "Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy", Journal of Experimental Medicine, (20010319), vol. 193, no. 6, pages 727 - 740, XP055059258 DOI: http://dx.doi.org/10.1084/jem.193.6.727
		- MANCINO et al., "Breast Cancer Increases Osteoclastogenesis by Secreting M-CSF and Upregulating RANKL in Stromal Cells", JOURNAL OF SURGICAL RESEARCH, (20010000), vol. 100, no. 1, pages 18 - 24, XP055291193 DOI: http://dx.doi.org/10.1006/jsre.2001.6204

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p